EPISODE · Mar 3, 2026 · 24 MIN
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
from Research To Practice | Oncology Videos · host Dr. Neil Love
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00) Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32) Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52) Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46) CME information and select publications
NOW PLAYING
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m